Performance and Safety of the PHENIX LIBERTY, a Medical Device for Electrostimulation and Biofeedback, in the Treatment of Pelvic Static Disorders in Women With Urinary Incontinence.

Inclusion Criteria:

• Patient who is incontinent (involuntary loss of urine) and/or has an overactivebladder (pollakiuria defined as more than one nocturnal urination and more than sixdaytime urination or leakage per day); Incontinent patient requiring functionalrehabilitation of pelvic static disorders by electrostimulation and biofeedback;

• Adult patient (between 18 / 75 years old);

• Patient with at least one of the following symptoms related to a pelvic staticdisorder: pain, hypertonia, muscle weakness, decreased or loss of motor control,trophic abnormality;

• Patient who can make herself available to participate in the sessions regularly andwho believes that she will be able to complete the tenth treatment session no laterthan 8 weeks after V0;

• Patient who has signed the consent form to participate in the study;

• Patient physically and mentally willing and able, in the judgment of theinvestigator at the time of recruitment, to perform the procedures under study;

• Patient with social protection.

Exclusion Criteria:

• Patient with peripheral or central neurological involvement (perianal or perivulvarsensitivity disorder);

• Patient with BMI ≥30 kg/m²

• Patient who has had more than 3 deliveries;

• Patient with stroke, Alzheimer's, multiple sclerosis, spinal cord involvement,narrow lumbar canal, cauda equina syndrome, or cognitive and/or behavioralimpairment that may, in the practitioner's judgment, interact with theself-questionnaire or biofeedback assessment;

• Pregnant woman at the inclusion visit;

• Patient with an implanted pacemaker or spinal cord trainer;

• Patient with hypersensitivity to electrostimulation;

• Patient with such vaginal atrophy that an endovaginal probe cannot be used

• Patient with chronic or recurrent vaginal or urinary tract infection on long-termtreatment;

• Patient with vaginal pathology (undiagnosed bleeding, cancer in the area to betreated);

• Patient who has renounced her liberty by administrative or judicial sentence, or whois under guardianship or limited judicial protection;

• Patient participating in an interventional clinical trial or testing/having testedan investigational drug and/or medical device within 30 days prior to inclusion inthe study in relation to the relevant pathology;

• Patient who cannot read or write French;

• Patient refusing to participate in the study.